會員登入
註冊
Prepare to prevent #2:
We are excited to share insights from Prof. Cheng-Hsun Chiu, Deputy Superintendent at 長庚醫院. He is also the leader of Advagene Biopharma's COVID-19 drug AD17002-SC's phase 2a trial.
Prof. Chiu emphasizes the critical need for a "Virology to Clinical Blueprint" and the NIH's "Phenotypic Approach" to prepare against future pandemics.
Stay updated with #Globalbio! Read more: https://lnkd.in/gjNyYDJY
#ChangGungHospital #HealthResearch #Pandemic #AdvageneBiopharma #Vaccine
Prof. Cheng-Hsun Chiu emphasizes the critical need for a "Virology to Clinical Blueprint"
撰文GlobalBio & Investment
日期2023-12-31
Prof. Cheng-Hsun Chiu emphasizes the critical need for a "Virology to Clinical Blueprint"
